Palvella Therapeutics (PVLA) Debt to Equity (2013 - 2025)
Palvella Therapeutics (PVLA) reported Debt to Equity of $0.08 for Q4 2025, up 148.39% year-over-year from $0.03 in Q4 2024, and up 36.99% on a QoQ basis from $0.06 in Q3 2025.
Palvella Therapeutics (PVLA) has 4 years of Debt to Equity data on file, last reported at $0.08 in Q4 2025.
- Quarterly Debt to Equity rose 148.39% year-over-year to $0.08 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $0.08 (up 148.39% YoY) and the FY2025 annual result came in at $0.08, up 148.39% from the prior year.
- Debt to Equity climbed to $0.08 in Q4 2025 per PVLA's latest filing, from $0.06 in the prior quarter.
- Across five years, Debt to Equity topped out at $0.08 in Q4 2025 and bottomed at $0.03 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.06 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.08 |
| Sep 30, 2025 | 0.06 |
| Jun 30, 2025 | 0.04 |
| Mar 31, 2025 | 0.04 |
| Dec 31, 2024 | 0.03 |
| Dec 31, 2014 | 0.07 |
| Sep 30, 2014 | -4.37 |
| Jun 30, 2014 | 0.09 |
| Mar 31, 2014 | -0.52 |
| Dec 31, 2013 | 2.82 |
| Jun 30, 2013 | 0.10 |